AbstractPurpose To compare sotorasib versus docetaxel monotherapy real-world outcomes in second line and beyond (2 L+) for locally advanced or metastatic non-small cell lung cancer (NSCLC). Methods The Cancer Analysis System includes English registration data. Sotorasib-treated patients with KRAS G12C-mutated NSCLC were compared with docetaxel-treated patients with NSCLC. Outcomes included overall survival (OS), time to next treatment or death (TTNTD), and time to treatment discontinuation or death (TTDD). The study period was 01 January 2013‒31 May 2024. The index date was the earliest date of initiation of sotorasib (01 March 2021–31 May 2024) or docetaxel monotherapy (01 January 2017‒31May 2024) in 2 L+. Propensity score weighting balanced baseline characteristics. Results The analysis included 1,665 patients (394 sotorasib; 1,271 docetaxel). Adjusted median OS was 10.18 months (95% confidence interval CI: 9.10‒12.02) with sotorasib and 6.87 (95% CI: 6.01‒7.82) with docetaxel (P P P P 0.001). Adjusted median TTDD was 5.06 (95% CI: 4.34‒6.11) and 2.30 months (95% CI: 2.07, 2.76) with sotorasib and docetaxel, respectively (P 0.001). Conclusion Sotorasib was associated with significantly improved OS, TTNTD, and TTDD compared with docetaxel in 2 L+ for locally advanced or metastatic NSCLC under real-world conditions in England.
Karim et al. (Fri,) studied this question.